We're doing some maintenance on our website between Thursday 9 May 2024 and Monday 13 May 2024. If you encounter any issues accessing our website during this time, you may need to refresh your browser to continue.
Biotome – Developing new methods of cancer screening
Biotome – R&D Tax Incentive customer story
Biotome develops next generation antibody diagnostic tools.
Having access to this R&D Tax Incentive is very helpful. It reduces the risks, or the demands, of capital raising. It’s been a very smooth process for us to work with AusIndustry.
Company Profile
Company: Biotome Pty Ltd
Sector: Biotechnology
Location: Perth, WA
Profile: Biotome Pty Ltd is a Perth-based biotechnology company that develops next generation antibody diagnostic tools. Their solutions combine modern technology with precision immunology to address the problems of traditional serology tests.
Biotechnology companies often conduct R&D that includes clinical trials to demonstrate efficacy of new products and processes, such as drugs or diagnostic tools. Companies who conduct R&D that involves clinical trials may be able to rely on the R&DTI clinical trials determination to register their core R&D activities under the program. The determination is designed to help biotechnology companies like Biotome access the R&DTI with greater certainty and less effort.
We use cookies to give you a better experience on our website. Learn more about how we use cookies and how you can select your preferences.